ASX 300 company Starpharma Holdings (ASX:SPL) is heading to market with a capital raising.
Starpharma is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.
Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses.
The ASX has granted a trading halt, with its shares placed in pre-open.
The halt will remain in place until the opening of trade on Monday 22nd September 2014, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.